(A1)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

G00002

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064210 A3

(51) International Patent Classification[7]: A61P 3/10, A61K 45/06, 31/352

(21) International Application Number: PCT/US01/50840

(22) International Filing Date: 25 October 2001 (25.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/244,225 30 October 2000 (30.10.2000) US

(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(72) Inventor: CONNOR, Gregory, S.; 6585 South Yale, Suite 620, Tulsa, OK 74136 (US)

(74) Agents: JOHNSON, Philip, S. et al., Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
6 March 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

162162

WO 02/064210 A3

(54) Title: COMBINATION THERAPY COMPRISING ANTI-DIABETIC AND ANTICONVULSANT AGENTS

(57) Abstract: Combination therapy comprising anti-diabetic agents and anticonvulsant derivatives useful for the treatment of Type II diabetes mellitus and Syndrome X are disclosed.